“I am very happy to be an advocate these days because so many good things have started to happen in the last three, four, five years. The number of survivors are increasing all the time, so it is very good to be able to say that,” said Tommy Björk, LuCE board member. He considered the dramatic advancements in the understanding of lung cancer over the years has lead to better outcomes for patients and advocated for patients’better access to clinical studies.
Follow LuCE event on 28th November at the EU Parliament that will focus on the current challenges in clinical trials across Europe. Within the occasion of this event, the 3rd edition of the LuCE report, which highlights some of the challenges still faced regarding research, will be presented.